Soluble and Ceil Surface Bound Adhesion Molecules in Blood and Cerebrospinal Fluid as Diagnostic Markers and Parameters for Disease Activity, Disease Severity and Treatment Efficacy in Patients with Multiple Sclerosis;Lösliche und Ceil-Oberfläche gebundene Adhäsionsmoleküle in Blut und Zerebrospinalflüssigkeit als diagnostische Marker und Parameter für Krankheitsaktivität, Krankheitsschwere und Behandlung Wirksamkeit bei Patienten mit Multiple Sklerose

LaboratoriumsMedizin

Volumn 25, Issue 11-12, 2001, Pages 548-556

  Kraus, J ^a   Kühne, Benedikte S ^a   Kaps, M ^a   Oschnnann, P ^a   Laske, C ^a   Stolz, E ^a   Engelhardt, Britta ^b   Traupe, H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; METHYLPREDNISOLONE;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GERMANY; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PATHOGENESIS; RELAPSE; REMISSION;

EID: 0035673697     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labm.2001.25.11-12.548     Document Type: Article

References (41)

1. Lassmann, H., Zimprich, F., Rossler, K., Vass, K. Inflammation in the nervous system. Basic mechanisms and immunological concepts. Rev Neurol (Paris) 1991:147(12):763-81.
2. Raine, CS. Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 1991:17(4): 265-74.
3. Traugott, U., Reinherz, EL, Raine, CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 1983, 219(4582):308-10.
4. Galopa, M., Bas, J., Mestre, M., Arbizu, T. Peres, J., Buendia, E. T cell subsets in multiple sclcrosis: a serial study. Acta Neurol Scand 1995; 92(5):361-8.
5. Zaffaroni, M., Gallo, L., Ghezzi, A., Cazzullo, CL. CD4+ lymphocyte subsets in the cerebrospinal fluid of multiple sclerosis and noninflammatory neurological diseases. J Neurol 1991; 238(4):209-11.
6. Hafler, DA. Weiner, HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989: 10(3): 104-7.
7. Lassmann, H., Vass, K. Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Springer Semin Immunopathol 1995; 17(1):77-87.
8. McMurray, RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996; 25(4):215-33.
9. Rothlein, R., Dustin, ML, Mariin, SD, Springer, TA. A human intercellular adhesion molecule (ICAM-I) distinct from LFA-1. J Immunol 1986; 137(4): 1270-4.
10. Acevedo, A., del Pozo, MA, Arroyo, AG, Sanchez-Mateos, P., Gonzalez-Amaro, R., Sanchez-Madrid, F. Distribution of ICAM-3-bear-ing cells in normal human tissues. Expression of a novel counterreceptor for LFA-1 in epidermal Langerhans cells. Am J Pathol 1993;143(3):774-83.
11. IL Makgoba, MW, Sanders, ME, Ginther Luce, GE. Dustin, ML, Springer, TA, Clark, EA, Mannoni, P., Shaw, S. ICAM-I a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature 1988: 331(615):86-8.
12. Sharief, MK, Noori, MA, Ciardi, M., Cirelli, A., Thompson, EJ. Increased levels of circulating ICAM-l in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 1993;43(1-2):15–21.
13. Diamond, MS, Staunton, DE, de Fougerolles, AR, Stacker, SA, Garcia-Aguilar, J., Hibbs, ML, Springer, TA. ICAM-l (CD54): a counter-receptor for Mac-1 (GDI lb/CD 18). J Cell Biol 1990:111(6Pt 2):3129-39.
14. Fawcett, J. Holness, CL, Needham, LA, Turley, H., Gatter, KC, Mason, DY, Simmons, DL. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992; 360(6403):481-4.
15. Campanero, MR, del Pozo, MA, Arroyo, AG, Sanchez-Mateos, P., Hemandez-Caselles, T., Craig, A., Pulido, R., Sanchez-Madrid, F. ICAM-3 interacts with LFA-1 and regulates the LFA-l/lCAM-1 cell adhesion paithway. J Cell Biol 1993; 123(4): 1007-16.
16. Droogan, AG. McMillan, SA, Douglas, JP, Hawkins, SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 1996:64(2): 185-91.
17. Martin, S., Rieckmann, P., Melchers, I., Wagner, R., Bertrams, J., Voskuyl, AE. Roep, BO, Zielasek, J., Heidenthal, E., Weichselbraun, I. Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1. J Immunol 1995: 154(4): 1951-5.
18. Rieckmann, P., Martin, S., Weichselbraun, I., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Luer, W., Helwig, A. Serial analysis of circulating adhesion molecules and TNF receptor in seruni from patients with multiple sclerosis: clCAM-1 is an indicator for relapse. Neurology 1994; 44(12):2367-72.
19. Tsukada, N., Matsuda, M., Miyagi, K., Yanagisawa, N. Increased levels of intercellular adhesion molecule-1 (lCAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993:43(12):2679-82.
20. Dore-Duffy, P., Newman, W., Balabanov, R., Lisak, RP, Mainolti, E., Rothlein, R., Peterson, M. Circulating, soluble adhesion proteins in cerebrospinal fluid and.serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37(1):55–62.
21. Hariung, HP, Michels, M., Reiners, K., Seeldrayers, P. Archelos, JJ. Toyka, KV. Soluble ICAM-I scrum levels in mulfiple sclerosis and viral encephalitis. Neurology 1993;43(11):2331-5.
22. Hartung, HP, Archelos, JJ, Zielasek, J., Gold, R., Koltzenburg, M., Reiners, KH, Toyka, KV. Circulating adhesion molecules and inflammatory mediators in demyeiination: a review. Neurology 1995; 45(6Suppl 6):S22-S32.
23. Matsuda, M., Tsukada, N., Miyagi, K., Yanagisawa, N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 1995;59(1-2);35–40.
24. Tsukada, N., Miyagi, K. Matsuda, M., Yanagisawa, N. Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type l-associated myelopathy. Ann Neurol 1993;33(6):646-9.
25. Calabresi, PA, Pelfirey, CM, Tranquill, LR, Maloni, H., McFarland, HF. VLA-4 expression on peripheral blood lymphocytes is down-regulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49(4);1111-6.
26. Elovaara, I. Laila, M., Spare, E., Lehtimaki, T. Dastidar, P. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 1998:51(6): 1703-8.
27. Crucian, B., Dunne, P., Friedman, H., Ragsdale, R. Pross, S., Widen, R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diasn Lab Immunol 1995; 2(2):249-52.
28. Qin, Y., Van Den, NS, Kurt, J., Gupta, S. Dual expression of CD45RA and CD45RO isoforms on myelin basic protein-specific CD4+ T-cell lines in multiple sclerosis. J Clin Immunol 1993; 13(2): 152-61.
29. PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1998;352 (9139):1498–1504.
30. Jacobs, LD, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, Fischer, JS, Goodkin, DE, Granger, CV, Simon, JH, Alam, JJ. Bartoszak, DM, Bourdette, DN, Braiman, J., Brownscheidlc, CM, Coats, ME, Cohan, SL, Dougheny, DS, Kinkel, RP, Mass, MK, Munschauer, FE, III, Priore, RL, Pullicino, PM. Scherokman, BJ. Whitham, RH. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285-94.
31. Johnson, KP, Brooks, BR, Cohen, JA, Ford, CC, Goldstein, J. Lisak, RP, Myers, LW, Panitch, HS, Rose, JW, Schiffer, RB. Copolymerl reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer I Multiple Sclerosis Study Group. Neurology 1995:45(7): 1268-76.
32. Paty, DW, Li, DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43(4):662-7.
33. Miller, DH. Albert, PS. Barkhof, F. Francis, G., Frank, JA. Hodgkinson, S., Lublin, FD, Paty, DW, Reingold, SC, Simon, J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39(1):6–16.
34. Kraus, J., Oschmann, P., Engelhardt, B., Schiel, C., Hornig, C., Bauer, R., Kern, A., Traupe, H., Domdorf, W. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998:98(2): 102-9.
35. Kraus, J., Oschmann, P., Engelhardt, B., Bauer, R., Schiel, C., Kern, A. Stolz, E., Traupe, A., Dorndorf, W. Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity. Acta Neurol Scand 2000; 101(2): 135-9.
36. Kraus, J., Oschmann, P., Engelhardt, B., Stolz, E., Kuehne, BS, Laske, C., Schaefer, C., Traupe, H., Kaps, M. CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis. Acta Neurol Scand 2000;102(5):326-32.
37. BoL Peterson, JW, Mork, S., Hoffman, PA. Gallatin, WM, Ransohoff, RM, Trapp, BD. Distribution of immunoglobulin superfamily members ICAM-1,-2,-3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996:55; 1060-72.
38. Bruck, W., Bitsch, A., Kolenda, H. Bruck, Y., Stiefel, M., Lassmann, H. Inflammatory central nervous.system demyeiination: correlation of magnetic resonance ima«ins findings with lesion pathology. Ann Neurol 1997;42:783-93.
39. Franciotta, D., Piccolo, G., Zardini, E. Bergamaschi, R., Cosi, V. Soluble CD8 and lCAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. Acta Neurol Scand 1997:95(5):275-9.
40. Pitzalis, C., Sharrack, B. Gray, IA, Lee, A., Hughes, RA. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J Neuroimmunol 1997; 74(1-2):62-8.
41. Gonzalez-Alvaro, I., Carmona, L., Diaz-Gonzalez, F., Gonzalez-Amaro, R., Mollinedo, F., Sanchez-Madrid, F., Laffon, A. Garcia-Vicuna, R. Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheumatol 1996;23(4):723-9.